TAGCyx Biotechnologies

About TAGCyx Biotechnologies

TAGCyx Biotechnologies Inc. operates as a preclinical-stage biotechnology firm centered on nucleic acid-based drug discovery and development. The company was established in March 2007 as a spin-out from the Japanese scientific research institute, RIKEN, by Dr. Ichiro Hirao. Dr. Hirao, a researcher with a Ph.D. in the chemical synthesis of RNA, developed the foundational artificial base pair technology that underpins the company's platform. Initially, TAGCyx aimed to commercialize this technology for applications like anti-counterfeiting for currency and research reagents. However, the business model proved challenging due to limited demand.

In 2016, the company underwent a significant strategic pivot to focus exclusively on drug discovery. This shift was championed by Chizuko Koseki, Ph.D., who joined as a consultant in 2015 and became President and CEO in 2017. The company's core asset is its proprietary drug discovery platform, Xenoligo®, which utilizes genetic alphabet expansion through artificial base pairs to generate highly functional DNA aptamers. These aptamers are single-stranded DNA molecules engineered to bind to specific disease-causing proteins with high affinity and specificity, functioning similarly to antibodies but with potential advantages such as lower immunogenicity and cost-effective chemical synthesis. The Xenoligo® platform enhances aptamer stability in the bloodstream through a proprietary "mini-hairpin" structure and improves target binding via hydrophobic interactions from the artificial bases.

The company's business model revolves around leveraging the Xenoligo® platform to develop a pipeline of therapeutic candidates and then partnering with larger pharmaceutical and biotech companies for further development and commercialization. This strategy generates revenue through upfront payments, development and sales milestone payments, and royalties on future sales from these licensing agreements. Its primary clients are pharmaceutical companies seeking to expand their treatment portfolios. The development pipeline focuses on areas such as autoimmune diseases, immunodermatology, hematological diseases, and conditions where therapies safe for pregnant women are needed. Key pipeline products include TAGX-0003, an IFN-γ antagonist for treating conditions like alopecia areata and vitiligo, which has been licensed to CAGE Bio for worldwide development and commercialization (excluding Japan). Other pipeline candidates are being investigated for Hunner-type interstitial cystitis, dry eye, and thrombotic thrombocytopenic purpura.